Skip to main content
. 2015 Feb 13;10(2):e0117062. doi: 10.1371/journal.pone.0117062

Table 5. Effects of METH on subjective and physiological measures in the consolidation group (n = 31).

Measure Placebo 10 mg 20 mg Dose (F 1, 30)
Feel—DEQ -0.4 (0.26) -0.01 (0.3) 0.8 (0.53) 3.62
Like—DEQ -0.65 (0.28) 0.4 (0.37)* 1.42 (0.63)* 8.98
Dislike—DEQ -0.61 (0.32) -0.53 (0.38) -0.11 (0.29) 0.86
High—DEQ -0.12 (0.2) 0.05 (0.29) 0.66 (0.42) 2.15
Take Again—DEQ -0.45 (0.26) 0.89 (0.35)* 1.9 (0.57)* 16.26
Anxiety—POMS -0.14 (0.27) -0.21 (0.85) 1.74 (0.57)* 7.78
Elation—POMS -0.09 (0.32) 1.48 (0.5)* 2.77 (0.66)* 19.37
Fatigue—POMS 0.12 (0.39) -1.21 (0.52) -1.26 (0.58) 3.05
Depression—POMS -0.16 (0.21) -0.64 (0.22) 0.01 (0.28) 0.26
Confusion—POMS -1.4 (0.53) -1.38 (0.5) -1.64 (0.74) 0.14
Vigor—POMS -0.3 (0.56) 1.47 (0.57)* 4.52 (1.06)* 20.21
Arousal—POMS 0.84 (1.18) 3.85 (1.42) 9.15 (2.31)* 15.21
Positive Mood—POMS 0.07 (0.4) 2.12 (0.52)* 2.77 (0.8)* 12.71
Systolic blood pressure (mmHg) -2.23 (0.96) 2 (1.13)* 5.25 (0.94)* 29.68
Diastolic blood pressure (mmHg) -0.64 (0.89) 2.43 (0.82)* 5.03 (0.83)* 18.78
Heart rate (bpm) -2.86 (1.29) 1.36 (0.91)* 1.94 (0.81)* 13.42

Data are change from pre-TX baseline means (SEM) averaged across time from +20 to +240 min post-capsule, and corresponding F-values from one-way repeated measures ANOVA examining linear main effects of drug dose. Bold values indicate a significant linear main effect of drug dose (p<.05).

*p<.05 compared to placebo.